BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15946974)

  • 1. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy.
    Pasini F; de Manzoni G; Pedrazzani C; Grandinetti A; Durante E; Gabbani M; Tomezzoli A; Griso C; Guglielmi A; Pelosi G; Maluta S; Cetto GL; Cordiano C
    Ann Oncol; 2005 Jul; 16(7):1133-9. PubMed ID: 15946974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase 2 study.
    Pasini F; de Manzoni G; Zanoni A; Grandinetti A; Capirci C; Pavarana M; Tomezzoli A; Rubello D; Cordiano C
    Cancer; 2013 Mar; 119(5):939-45. PubMed ID: 23165781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer.
    Hihara J; Yoshida K; Hamai Y; Emi M; Yamaguchi Y; Wadasaki K
    Anticancer Res; 2007; 27(4C):2597-603. PubMed ID: 17695421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Study of Docetaxel, Cisplatin, and 5-Fluorouracil Chemoradiotherapy for Local or Metastatic Esophageal Cancer.
    Iwasaki K; Osaka Y; Tachibana S; Suda T; Ota Y; Hoshino S; Tsuchida A
    Anticancer Res; 2016 Mar; 36(3):987-94. PubMed ID: 26976988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer.
    Allal AS; Zwahlen D; Becker M; Dulguerov P; Mach N
    Cancer J; 2006; 12(1):63-8. PubMed ID: 16613664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
    Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Matsumura S; Iwahashi M; Yamaue H
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26725778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
    Kong L; Zhang YW; Hu CS; Guo Y
    Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study).
    Nakamura K; Kato K; Igaki H; Ito Y; Mizusawa J; Ando N; Udagawa H; Tsubosa Y; Daiko H; Hironaka S; Fukuda H; Kitagawa Y;
    Jpn J Clin Oncol; 2013 Jul; 43(7):752-5. PubMed ID: 23625063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
    Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
    Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study.
    Lanciano R; Calkins A; Bundy BN; Parham G; Lucci JA; Moore DH; Monk BJ; O'Connor DM
    J Clin Oncol; 2005 Nov; 23(33):8289-95. PubMed ID: 16230678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial.
    Roth AD; Maibach R; Fazio N; Sessa C; Stupp R; Morant R; Herrmann R; Borner MM; Goldhirsch A; de Braud F
    Ann Oncol; 2004 May; 15(5):759-64. PubMed ID: 15111343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study.
    Tanaka Y; Yoshida K; Sanada Y; Osada S; Yamaguchi K; Takahashi T
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1159-65. PubMed ID: 20878160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.
    Ma HB; Di ZL; Wen J; Ke Y; Sun X; Ren J
    Jpn J Clin Oncol; 2015 Feb; 45(2):169-75. PubMed ID: 25416813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
    Weiner LM; Colarusso P; Goldberg M; Dresler C; Coia LR
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
    Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
    Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer.
    Wang B; Zhang W; Hong X; Guo Y; Li J
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):213-8. PubMed ID: 18343924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).
    Higuchi K; Koizumi W; Tanabe S; Sasaki T; Katada C; Ishiyama H; Hayakawa K
    Radiother Oncol; 2008 Jun; 87(3):398-404. PubMed ID: 18405987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.